• A predictive classifier of poor prognosis in transplanted patients with juvenile myelomonocytic leukemia: a study on behalf of the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire
• Advances in molecular evaluation of myeloproliferative neoplasms
• Allogeneic Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia with a Busulfan, Fludarabine, and Melphalan Regimen: JPLSG JMML-11
• Allogeneic hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia with intestinal Behcet's disease: A case report
• Assessment of Ecotropic Viral Integration Site 2B (EVI2B) Gene in Juvenile Myelomonocytic Leukemia and Neurofibromatosis Type 1 NF1 Tumors
• Azacitidine (Vidaza^®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)
• BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
• Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup
• Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss
• Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ): Patient Version
• Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®): Health Professional Version
• Chronic myeloproliferative neoplasm in adulthood in CBL syndrome harboring a splice-site <em>CBL</em> variant alongside a novel constitutional <em>CSF3R</em> variant
• Clinical and molecular features of <em>CBL</em>-mutated juvenile myelomonocytic leukemia
• Clinical and Osteopetrosis-Like Radiological Findings in Patients with Leukocyte Adhesion Deficiency Type III
• Clinical features and prognosis of juvenile myelomonocytic leukemia: an analysis of 63 cases
• Combined Haploidentical Hematopoetic Stem Cell Transplantation and Liver Transplantation in a Pediatric Patient
• Cutaneous Vasculitis as the Initial Presentation of Juvenile Myelomonocytic Leukemia
• Droplet digital PCR: An effective method for monitoring and prognostic evaluation of minimal residual disease in JMML
• Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group
• Epigenetic Profiling of <em>PTPN11</em> Mutant JMML Hematopoietic Stem and Progenitor Cells Reveals an Aberrant Histone Landscape
• Erratum: Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay
• Estimating the prevalence of pediatric hematological malignancies in Al-Madinah Al-Munawwarah, Saudi Arabia
• Germline bi-allelic <em>SH2B3/LNK</em> alteration predisposes to a neonatal juvenile myelomonocytic leukemia-like disorder
• Germline bi-allelic SH2B3/LNK alteration predisposes to a neonatal juvenile myelomonocytic leukemia-like disorder
• Germline Neurofibromin 1 mutation enhances the anti-tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity
• Histopathological findings of anterior lens capsule in pediatric cataract
• Identifying Potential SOS1 Inhibitors via Virtual Screening of Multiple Small Molecule Libraries against KRAS-SOS1 Interaction
• Identifying Potential SOS1 Inhibitors via Virtual Screening of Multiple Small Molecule Libraries against KRAS-SOS1 Interface
• Immunological and hematological findings as major features in a patient with a new germline pathogenic CBL variant
• In vivo Targeting MEK and TNK2/SRC pathways in PTPN11 driven leukemia
• Infantile Disseminated Bacille Calmette-Guerin Disease with Hemophagocytosis and Mimicking Juvenile Myelomonocytic Leukemia: A Case Report with Concise Literature Review
• Juvenile myelomonocytic leukemia and pediatric myelodysplastic syndromes
• Juvenile Myelomonocytic Leukemia Treatment (PDQ): Health Professional Version
• Leukemoid Reaction due to Chorioamnionitis Mimicking Juvenile Myelomonocytic Leukemia in an Infant
• LNK/<em>SH2B3</em> as a novel driver in juvenile myelomonocytic leukemia
• LNK/SH2B3 as a novel driver in juvenile myelomonocytic leukemia
• Long-term remission of infantile Takayasu arteritis associated with germline CBL syndrome after allogeneic hematopoietic stem cell transplantation: A case report and literature review
• Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®): Patient Version
• Neurofibromatosis Symptom-Lacking B-Cell Lineage Acute Lymphoblastic Leukemia with Only an <em>NF1</em> Gene Pathogenic Variant
• Noonan Syndrome-related Myeloproliferative Disorder Occurring in the Neonatal Period: Case Report and Literature Review
• Observation and Management of Juvenile Myelomonocytic Leukemia and Noonan Syndrome-Associated Myeloproliferative Disorder: A Real-World Experience
• Pediatric Hematopathology in the era of advanced molecular diagnostics: what we know and how we can apply the updated classifications
• Phenotypic profiling of CD34+ cells by advanced flow cytometry improves diagnosis of Juvenile Myelomonocytic Leukemia
• Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases
• Prototypical innate immune mechanism hijacked by leukemia-initiating mutant stem cells for selective advantage and immune evasion in Ptpn11-associated juvenile myelomonocytic leukemia
• Refining risk stratification to improve prognosis in juvenile myelomonocytic leukemia
• Response to chemotherapy in juvenile myelomonocytic leukemia and its clinical implications for survival: A retrospective registry-based study of the Korean Pediatric Hematology-Oncology Group
• Severe RAS-Associated Lymphoproliferative Disease Case with Increasing αβ Double-Negative T Cells with Atypical Features
• SH2B3 alterations in a novel genetic condition, juvenile myelomonocytic leukemia, and myeloproliferative neoplasia
• Successful second allogeneic hematopoietic stem cell transplantation with azacitidine as bridging therapy for relapsed juvenile myelomonocytic leukemia
• Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia
• The elevation of red blood cell distribution width is an independent prognostic factor for juvenile myelomonocytic leukemia
• Therapeutic efficacy of RAS inhibitor trametinib using a juvenile myelomonocytic leukemia patient-derived xenograft model
• Too many white cells-TAM, JMML, or something else?
• Transient Leukoerythroblastic Reaction in a Newborn with Rh-Incompatibility and Hemolysis: Case Report and Literature Review
• Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay
• Two Cases of Juvenile Myelomonocytic Leukemia and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease